Cancer Patients Gain Disease Protection After mRNA Vaccination
July 8, 2021 • 11:11 am CDT (Precision Vaccinations) The JAMA Oncology published the results from a cohort study 'Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.' On July 8, 2021, this Original Investigation concluded by saying, 'In this cohort study of 223 cancer patients, the SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech, Comrinaty) appeared to be safe and achieve satisfactory serologic status.' 'There was a pronounced lag in antibody production compared with the rate in noncancer controls.' 'However, seroconversion occur...
Source: precisionvaccinations.com